Related Experiment Video
Updated: Oct 6, 2025

Simultaneous Application of Transcranial Direct Current Stimulation during Virtual Reality Exposure
Published on: January 18, 2021
Adjunctive Minocycline for Treatment of Posttraumatic Stress Disorder
Anna Gerst1, Tej Murthy1, Alisandrea Elson1,2
1Creighton University School of Medicine, Omaha, Nebraska.
Introduction:
Posttraumatic stress disorder (PTSD) is a chronic, debilitating anxiety disorder. While there is evidence that antibiotics such as minocycline may help to improve symptoms in some psychiatric disorders, no human studies have evaluated their potential as a treatment for PTSD.
Methods:
We present results from 4 men aged 33 to 59 years who completed a 12-week pilot, prospective, nonrandomized, open-label clinical trial of adjunctive minocycline for veterans diagnosed with PTSD.
Results:
All 4 patients showed reduction in PTSD symptoms at the end of the 12-week study, and 3 patients showed reduction in depression symptoms. Observed changes in inflammatory biomarkers are discussed.
Discussion:
Previous studies have reported increased inflammation in PTSD, though evidence of a potential therapeutic effect of minocycline for PTSD has not been reported previously in humans.
Conclusion:
These findings suggest that antibiotics like minocycline may help to reduce symptoms of PTSD, though further investigation is needed to confirm these findings.
Insights
Minocycline, an antibiotic, may reduce symptoms of posttraumatic stress disorder (PTSD) in veterans. This pilot study showed symptom reduction in all participants receiving minocycline as a PTSD treatment.
Area of Science:
- Neuroscience
- Pharmacology
- Psychiatry
Background:
- Posttraumatic stress disorder (PTSD) is a significant mental health condition.
- Existing treatments for PTSD have limitations.
- Minocycline, an antibiotic, has shown potential in other psychiatric disorders, but its efficacy in PTSD is unstudied in humans.
Observation:
- A 12-week open-label pilot study was conducted with four male veterans diagnosed with PTSD.
- Participants received adjunctive minocycline treatment.
- The study monitored PTSD and depression symptoms, as well as inflammatory biomarkers.
Findings:
- All four participants experienced a reduction in PTSD symptoms.
- Three participants also showed a decrease in depression symptoms.
- Changes in inflammatory biomarkers were observed and will be discussed.
Implications:
- These preliminary findings suggest minocycline may be a potential therapeutic agent for PTSD.
- Further research is warranted to validate these results in larger, controlled trials.
- Minocycline could offer a novel treatment avenue for PTSD, potentially by modulating inflammation.
More Related Videos
08:25Polar Histogram Visualization of Acute Stress Disorder Scale Scores for Comprehensive Clinical Assessment
Published on: December 6, 2024
10:43Developing Neuroimaging Phenotypes of the Default Mode Network in PTSD: Integrating the Resting State, Working Memory, and Structural Connectivity
Published on: July 1, 2014
Related Concept Videos
Post-traumatic Stress Disorder
Symptoms and Behavioral Manifestations
A spectrum of distressing symptoms characterizes PTSD. Recurrent flashbacks, where individuals involuntarily relive traumatic events,...
Treatment Strategies for Psychological Disorders
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Antidepressant Drugs: MAOIs and Other Agents
Drug Therapy
Antianxiety Medications
Antidepressant Drugs: Overview
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs